Clinical and economic consequences of ozenoxacin vs. other topical antibiotics for the treatment of impetigo: a real-life study in Spain
Open Access
- 18 October 2022
- journal article
- research article
- Published by Aboutscience Srl in Global and Regional Health Technology Assessment
- Vol. 9, 133-137
- https://doi.org/10.33393/grhta.2022.2439
Abstract
Background: Impetigo is a common dermatological paediatric infection that can be treated with topical antibiotics: the common are mupirocin (MUP), fusidic acid (FA) and, most recently, ozenoxacin (OZ). Aim: This study assesses the clinical and economic consequences of the use of OZ vs. MUP and vs. FA for the treatment of impetigo in routine clinical practice in Spain. Methods: This is a retrospective observational study using real-life data from electronic medical records of patients with impetigo who started treatment with OZ, MUP or FA (maximum follow-up: 3 months; n = 10,974). We compared treatment duration, comorbidities, use of systemic medication, complications, utilization of resources and associated costs across treatments (pResults: Mean age was 12.6 (standard deviation [SD]: 16.6) years; 48.6% were male; treatment: 9.3% (OZ), 56.4% (MUP), 34.5% (FA). The percentage of patients ending treatment after 2 weeks was 87.6% (OZ) vs. 83.2% (MUP) vs. 82.4% (FA); pConclusions: OZ is a cost-effective and dominant alternative for the treatment of impetigo.Keywords
This publication has 6 references indexed in Scilit:
- Do Antimicrobial Resistance Patterns Matter? An Algorithm for the Treatment of Patients With ImpetigoJournal of Drugs in Dermatology, 2021
- PMU146 VALIDATION AND REPRESENTATIVENESS OF THE SPANISH BIG-PAC DATABASE: INTEGRATED COMPUTERIZED MEDICAL RECORDS FOR RESEARCH INTO EPIDEMIOLOGY, MEDICINES AND HEALTH RESOURCE USE (REAL WORD EVIDENCE)Value in Health, 2019
- Ozenoxacin: A Novel Topical Quinolone for ImpetigoAnnals of Pharmacotherapy, 2018
- Efficacy and Safety of Ozenoxacin Cream for Treatment of Adult and Pediatric Patients With ImpetigoJAMA Dermatology, 2018
- Ozenoxacin 1% cream in the treatment of impetigo: a multicenter, randomized, placebo- and retapamulin-controlled clinical trialFuture Microbiology, 2014
- Impetigo: diagnosis and treatment.2014